Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.
The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development. Lead programs target Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS), with the goal of providing long-term, one-time treatments to restore or preserve neuronal function. Voyager’s flagship clinical asset is VY-AADC, an AAV2 vector designed to deliver aromatic L-amino acid decarboxylase directly to regions of the brain affected by Parkinson’s pathology.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics collaborates with academic institutions, research hospitals and biopharmaceutical partners to advance its gene therapy programs. The company conducts clinical trials across multiple sites in the United States and Europe, leveraging strategic partnerships to support vector manufacturing, regulatory engagement and trial execution.
Voyager is led by a management team with deep expertise in gene therapy, neurology and biopharmaceutical development. Its scientific advisory board comprises leaders in neuroscience research, while its operational staff brings experience in regulatory affairs, clinical operations and process development. The company remains committed to translating cutting-edge science into transformative therapies for patients with debilitating neurological disorders.
AI Generated. May Contain Errors.
